跳至主要内容
临床试验/EUCTR2010-022627-29-IT
EUCTR2010-022627-29-IT进行中(未招募)不适用

Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine) - ND

OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2010年12月22日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age 18-70 years, serum HBsAg positivity for at least 6 months, na?vete` to (Peg)-interferons and nucleoside/nucleotide analogs, HBV-DNA levels = 7 Log10 copies/mL (HBeAg-negative patients) or = 9 Log10 copies/mL (HBeAg-positive patients).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Coinfection with HIV, HCV, HDV, evidence of hepatic decompensation or hepatocellular carcinoma, major comorbidities, alcohol or drug abuse, Pregnant or breastfeeding patients. Women of childbearing potential must have a negative serum betahuman chorionic gonadotropin (ß-HCG) during screening and use any combination of hormonal contraception

研究者

发起方
OSPEDALE POLICLINICO S. MATTEO

相似试验